FDA Grants Breakthrough Status to Bacterial-vs-Viral Blood Test

FDA Grants Breakthrough Status to Blood Test That Tells Bacteria from Virus

The FDA has granted Breakthrough Device designation to MeMed BV Flex, a blood test that rapidly distinguishes bacterial from viral infections using immune-response protein signatures, potentially reducing the antibiotic overprescribing that fuels antimicrobial resistance.

DT Editorial AI

Mar 22, 2026·2 min read·593 words

A Deceptively Simple Clinical Problem

Every day, clinicians face a diagnostic challenge that sounds straightforward but is not: is this patient's infection bacterial or viral? The distinction matters enormously. Bacterial infections require antibiotics; viral infections do not and cannot be treated with them. Prescribing antibiotics for viral infections is not merely ineffective — it actively contributes to antimicrobial resistance by exposing bacteria to sub-therapeutic antibiotic concentrations, selecting for resistant strains that can spread through communities and healthcare settings.

Yet distinguishing the two has historically been difficult at the point of care. Clinical symptoms overlap significantly: both bacterial and viral infections can cause fever, fatigue, elevated white blood cell counts, and the general pattern of systemic illness. Standard laboratory tests — complete blood count, C-reactive protein, procalcitonin — are useful but imprecise; they reflect the magnitude of an inflammatory response rather than its specific cause.

MeMed BV Flex takes a different approach. Instead of measuring a single inflammatory marker, it measures the body's own immune response signature — a panel of host proteins whose relative levels shift in characteristic patterns depending on whether the immune system is responding to a bacterium or a virus.

The Science Behind the Test

MeMed, an Israeli medical diagnostics company, developed the technology by collecting blood samples from thousands of patients with confirmed bacterial or viral infections and analyzing the proteomic patterns associated with each type. The analysis identified a combination of three proteins — tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C-reactive protein — whose combined levels generate a score that accurately classifies infections as bacterial or viral in a majority of clinical presentations.

TRAIL and IP-10 are markedly elevated by viral infections because they are part of the innate immune response specifically triggered by viral nucleic acids. CRP rises with both types but is generally higher in bacterial cases. The ratio and combination of the three markers provides specificity that no single marker achieves on its own, with accuracy rates that in clinical trials have outperformed individual biomarkers and clinical judgment in classifying ambiguous presentations.

What Breakthrough Device Designation Means

FDA's Breakthrough Device Program accelerates development and review for medical devices that provide more effective diagnosis or treatment of serious conditions than currently available alternatives. Designation does not mean the device is approved — it means the FDA commits to more interactive communication with the developer, prioritized review of submissions, and senior agency staff involvement in key decisions.

For MeMed BV Flex, the designation signals that FDA reviewers see the device's potential to address an unmet clinical need of sufficient importance to warrant expedited review. Given that the WHO describes antimicrobial resistance as one of the greatest threats to global health — causing approximately 1.27 million direct deaths annually — a test that reliably reduces inappropriate antibiotic prescribing in emergency departments and primary care settings could have substantial population-level impact.

The Stakes

Studies consistently show that respiratory tract infections, which are responsible for the majority of antibiotic prescriptions in primary care, are predominantly viral and do not benefit from antibiotic treatment. A reliable, rapid test that enables clinicians to confidently withhold antibiotics from patients with viral infection profiles would directly reduce the selection pressure driving resistance.

If MeMed BV Flex achieves FDA clearance and broad adoption, it could represent one of the more consequential diagnostic innovations in infectious disease management in recent years — not because it treats any disease, but because it provides the information needed to treat far fewer with drugs that should be conserved for when they are genuinely needed.

This article is based on reporting by Medical Xpress. Read the original article.

Health

A meningitis outbreak in southeast England linked to a nightclub has grown to 34 reported cases including 23 confirmed, prompting an urgent public health investigation, contact tracing, and prophylactic vaccination effort.

DT Editorial AI·Mar 22, 2026·via medicalxpress.com

Health

Stelios Papadopoulos, the financier who helped shape modern biotechnology, discusses the obesity drug revolution, AI's real role in drug discovery, and China's rising competitive threat.

DT Editorial AI·Mar 21, 2026·via statnews.com

Health

The head of Medicare has signaled that TrumpRx, the administration's drug pricing initiative, is intended to be limited in scope — tempering Wall Street expectations while raising questions about real-world patient impact.

DT Editorial AI·Mar 21, 2026·via statnews.com

Health

Roche's Genentech has abandoned late-stage development of a muscle-building drug in two rare genetic diseases, casting uncertainty on a parallel obesity trial testing the same compound.